Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2024-11-17 DOI:10.1016/j.vaccine.2024.126530

Jie Mao , Hae-Ji Kang , Gi-Deok Eom , Keon-Woong Yoon , Ki Back Chu , Fu-Shi Quan

{"title":"Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2","authors":"Jie Mao , Hae-Ji Kang , Gi-Deok Eom , Keon-Woong Yoon , Ki Back Chu , Fu-Shi Quan","doi":"10.1016/j.vaccine.2024.126530","DOIUrl":null,"url":null,"abstract":"<div><div>Influenza A matrix protein 2 (M2e) and neuraminidase (NA) antigens are known to play important roles in mounting a broad range of protection. Nonetheless, the protective efficacy of the VLP vaccines co-expressing both M2e and NA antigens has not been explored. In this study, we generated 2020/2021 seasonal influenza H3N1 VLPs that co-expressed either M2e5x (H3N1M2e5x) or N2 (H3N1N2 VLP) antigens. The protective efficacy of these VLPs was assessed by challenge infection with heterologous H3N2 and heterosubtypic H1N1 and H5N1 viruses in mice. Both VLP formulations induced cross-protection against distinct viruses, H3N1M2e5x VLPs elicited higher levels of cross-reactive IgG in sera against H1N1 and H5N1 viruses than H3N1N2 VLPs. Compared to H3N1N2 VLPs, H3N1M2e5x VLPs also induced substantially enhanced germinal center B cell responses while inhibiting IFN-γ production in the lungs. Importantly, H3N1M2e5x VLPs significantly reduced the lung virus titers upon H1N1, H3N2, and H5N1 challenge infections. These results indicated that VLPs comprising the M2e5x antigen are a promising vaccine design strategy that could aid in the pursuit of a universal influenza vaccine.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126530"},"PeriodicalIF":4.5000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X2401212X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Influenza A matrix protein 2 (M2e) and neuraminidase (NA) antigens are known to play important roles in mounting a broad range of protection. Nonetheless, the protective efficacy of the VLP vaccines co-expressing both M2e and NA antigens has not been explored. In this study, we generated 2020/2021 seasonal influenza H3N1 VLPs that co-expressed either M2e5x (H3N1M2e5x) or N2 (H3N1N2 VLP) antigens. The protective efficacy of these VLPs was assessed by challenge infection with heterologous H3N2 and heterosubtypic H1N1 and H5N1 viruses in mice. Both VLP formulations induced cross-protection against distinct viruses, H3N1M2e5x VLPs elicited higher levels of cross-reactive IgG in sera against H1N1 and H5N1 viruses than H3N1N2 VLPs. Compared to H3N1N2 VLPs, H3N1M2e5x VLPs also induced substantially enhanced germinal center B cell responses while inhibiting IFN-γ production in the lungs. Importantly, H3N1M2e5x VLPs significantly reduced the lung virus titers upon H1N1, H3N2, and H5N1 challenge infections. These results indicated that VLPs comprising the M2e5x antigen are a promising vaccine design strategy that could aid in the pursuit of a universal influenza vaccine.

查看原文本刊更多论文

共表达 M2e5x 或 N2 的 2020-2021 年季节性流感 H3N1 病毒样颗粒诱导的疫苗疗效。

众所周知，甲型流感基质蛋白 2（M2e）和神经氨酸酶（NA）抗原在提供广泛保护方面发挥着重要作用。然而，联合表达 M2e 和 NA 抗原的 VLP 疫苗的保护效力尚未得到探讨。在这项研究中，我们生成了2020/2021年季节性流感H3N1 VLP，它们同时表达M2e5x（H3N1M2e5x）或N2（H3N1N2 VLP）抗原。这些 VLP 的保护效力是通过小鼠挑战性感染异源 H3N2 病毒和异源亚型 H1N1 和 H5N1 病毒来评估的。与 H3N1N2 VLP 相比，H3N1M2e5x VLP 在血清中引起的针对 H1N1 和 H5N1 病毒的交叉反应 IgG 水平更高。与 H3N1N2 VLPs 相比，H3N1M2e5x VLPs 在抑制肺部 IFN-γ 生成的同时，还能诱导生殖中心 B 细胞反应的大幅增强。重要的是，H3N1M2e5x VLPs 能显著降低 H1N1、H3N2 和 H5N1 病毒挑战感染时的肺部病毒滴度。这些结果表明，包含M2e5x抗原的VLPs是一种很有前途的疫苗设计策略，有助于开发通用流感疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.